Gregory Stock Email and Phone Number
PhD in Biophysics, Johns Hopkins. MBA, Harvard. Adjunct Professor, Dept of Genetics and Genomic Sciences, Mt. Sinai School of Medicine. Founded Socratic Sciences to produce Fathm, a question-driven communications platform that catalyzes understanding, community and social connection at scale as an antidote to traditional social media. Co-founded the Harris Center for Precision Wellness at Icahn School of Medicine at Mt. Sinai, and the Program on Medicine, Technology, and Society at UCLA’s School of Medicine. Started and led two biotech companies, Signum Biosciences and Ecoeos. Author of eight books including Redesigning Humans, winner of the Kistler Science Book Prize, and The Book of Questions, the first in a series on ethics and values that has sold 5 million copies, been translated into 25 languages, and powered the work of Socratic Sciences. 1,000+ media appearances, including Nova, PBS, NPR, Larry King, and Oprah. Multiple broadcasted one-on-one policy debates with figures such as Ray Kurzweil, Jeremy Rifkin, Daniel Callahan, and Francis Fukuyama on the future of genetics and other topics at the intersection of emerging technology and the human future.
Fathm
View-
Chief Executive OfficerFathm Jan 2020 - PresentWe envision a world where conversation actually enriches our lives. We harness the science of questioning to push beyond the chatter, spark insights and understanding, deepen relationships, nurture community, and build trust. Fathm, the flagship offering of Socratic Sciences, harnesses the power of open-ended questioning to open up our lives, one question at a time. The core Fathm experience uses the Questioning methodology that drove the popularity of the best-selling The Book of Questions series by Dr. Gregory Stock.A Socratic Sciences project
-
Founder, CeoSocratic Sciences Jun 2018 - PresentSocratic Sciences has built upon the proven interpersonal communication methodologies of the best-selling The Book of Questions series to create The Game of Questions, a small-group, mobile-game experience. This play and learning platform integrates elements of social media, gaming, relationship building, and big data to provide a unique journey of human discovery and belonging. Data from the game is de-identified and aggregated into a potent Map of Human Identity to sharpen our sense of who we are, what we care about, and how we compare with others, and to provide a unique window into the human psyche. The game is in beta and moving towards a Q1 2022 launch.
-
Adjunct ProfessorIcahn School Of Medicine At Mount Sinai Jan 2019 - Present
-
Co-Director, Co-Founder, Harris Center For Precision WellnessIcahn School Of Medicine At Mount Sinai Jan 2015 - Jan 2019The Harris Center, part of the Icahn Institute for Genomics and Multiscale Biology at Mt. Sinai's School of Medicine, is leveraging its access to clinical populations and its expertise in big-data analytics to deepen the health value of the rich personal data clouds that have recently become feasible. The combination of extensive molecular omic data and physiologic tracking data can yield a rich, actionable portrait of a person's health. Such data can suggest effective paths to enhanced wellness and vitality, and provide early indications of impending problems while they are still amenable to preventive interventions.
-
Director, Co-FounderSignum Biosciences Sep 2003 - PresentDirector, Founding CEO (2003-2010). Signum has developed key science associated with cellular signal-transduction pathways. With less than $40 million in funding, it has partnered with Princeton, Rutgers, NYU, the Alzheimer’s Drug Discovery Foundation, and the NIH to pioneer a new class of anti-inflammatory molecules and tau-related therapeutics for Alzheimer's. Dermalogix, a Signum subsidiary, has partnered with Elizabeth Arden, Rohto, and other skincare companies to commercialize this anti-inflammatory technology. Nutralogix, another subsidiary, developed and sells a nutraceutical for brain health based on the tau-related technology.
-
Research Professor, Department Of Genetics And Genomic SciencesIcahn School Of Medicine At Mt. Sinai Jan 2015 - Jan 2019
-
DirectorNapo Pharmaceuticals Apr 2008 - Nov 2017Napo took a fast-tracked drug candidate, moved it into late-stage clinical trials, and partnered with Salix Pharmaceuticals to gain FDA approval for diarrhea associated with Antiretroviral Therapy for HIV. Crofelemer (now Fulyzag) – a New Chemical Entity derived from the latex of the croton lechleri tree in the Amazon basin - is the only oral botanical drug ever approved by the FDA. The drug shows promise for cholera-associated diarrhea and Irritable Bowel Syndrome as well as for pediatric diarrhea, the second biggest killer of children in the world. Veterinary use in companion and large animals is being orchestrated through our subsidiary, Jaguar Animal Health.
-
Co-Founder, Ceo/CsoEcoeos Jun 2010 - Apr 2014Founding CEO/CSO, Director (2010-2014). Working with the University of Washington and Mt. Sinai Medical School, Ecoeos develops genetic diagnostics to gauge personal vulnerability to environmental toxins. The company's first product is a consumer diagnostic to gauge a child’s risk of cognitive deficits from chronic exposure to supposedly “safe” low levels of mercury. This is important because one in five boys have a genetic sensitivity to mercury that could lead to developmental deficits in Attention and Memory averaging 3 to 5 years from Hg exposure that could be avoided.
-
Founding Director, Program On Medicine, Technology And SocietyUcla School Of Medicine Feb 1997 - Jun 2008Los Angeles, Ca, UsThe PMTS program at UCLA’s Medical School explored the most challenging social and policy issues raised by the biotech and genomics revolution. As part of its focus on the deep impacts of technological advances on the future of healthcare and society in general, the Program convened high-level panels and hosted high-profile symposia, one covered on the front page of the NY Times. PMTS, known for its focus on incorporating disruptive cutting-edge science in framing critical policy issues, led to the formation UCLA’s Institute for Society and Genetics.
Gregory Stock Education Details
-
Harvard Business SchoolEntrepreneurial And Small Business Operations -
The Johns Hopkins UniversityBiophysics
Frequently Asked Questions about Gregory Stock
What company does Gregory Stock work for?
Gregory Stock works for Fathm
What is Gregory Stock's role at the current company?
Gregory Stock's current role is CEO, Socratic Sciences; Founding Co-Director, Precision Wellness Center, Mt. Sinai Medical School; Founding CEO Signum Biosciences; Best-Selling Author; Public Speaker.
What schools did Gregory Stock attend?
Gregory Stock attended Harvard Business School, The Johns Hopkins University.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial